Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study

Part of paid clinical trials in Gilbert, Arizona.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT04739072
Status
Recruiting
Apply to this trial

Conditions

  • Colorectal Adenocarcinoma
  • Stage I Colorectal Cancer AJCC v8
  • Stage II Colorectal Cancer AJCC v8
  • Stage IIA Colorectal Cancer AJCC v8
  • Stage IIB Colorectal Cancer AJCC v8
  • Stage IIC Colorectal Cancer AJCC v8
  • Stage III Colorectal Cancer AJCC v8
  • Stage IIIA Colorectal Cancer AJCC v8
  • Stage IIIB Colorectal Cancer AJCC v8
  • Stage IIIC Colorectal Cancer AJCC v8
  • Stage IV Colorectal Cancer AJCC v6
  • Stage IVA Colorectal Cancer AJCC v8
  • Stage IVB Colorectal Cancer AJCC v8
  • Stage IVC Colorectal Cancer AJCC v8

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Biospecimen Collection — PROCEDURE
    Undergo collection of blood and tissue samples
  • Electronic Health Record Review — OTHER
    Review of medical records

Study Details

This study investigates if circulating tumor DNA (ctDNA) and other tumor-related molecules/chemicals released in the blood can help doctors predict if colorectal cancer may come back or spread. Tumors shed DNA and other cancer related chemicals into the blood that can be identified and studied further to provide information about the cancer. Information gathered from this study may help researchers better understand if ctDNA found in the blood can predict whether colorectal cancer may come back or spread.

Key Dates

Start date
Nov 22, 2019
Status verified
May 2026
Primary completion
Dec 31, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
1,000 participants (estimated)

Arms

  • Arm: Ancillary-correlative (biospecimen collection)
    Patients undergo collection of blood samples at baseline, during each neoadjuvant therapy treatment, prior to surgical resection, and up to 4 times per year for up to 5 years. Patients also undergo collection of tissue sample at time of surgical resection. Patients medical records may also be reviewed.

Primary Outcome Measure

Analysis of deoxyribonucleic (DNA), ribonucleic acid (RNA), and proteomic alterations from plasma [ Time Frame: Up to 5 years ]

Central Contacts

Locations (10)

FacilityCityStateZIPSite coordinators
Banner - MD Anderson Cancer CenterGilbertArizona85234-
Baptist- MD Anderson Cancer CenterJacksonvilleFlorida32207-
The Queen's Medical CenterHonoluluHawaii96813-
St. Luke's Cancer InstituteBoiseIdaho83712-
Cooper Hospital UNIV MED CTR.CamdenNew Jersey08103-
UT Southwestern/Simmons Cancer Center-DallasDallasTexas75390-
Houston Methodist Cancer CenterHoustonTexas77030-
M D Anderson Cancer CenterHoustonTexas77030
Arvind Dasari
[email protected]
713-792-2828
Arvind Dasari (PRINCIPAL_INVESTIGATOR)
UT Health San Antonio MD Anderson Cancer CenterSan AntonioTexas78229-
Baylor Scott & White Research InstituteTempleTexas76508-

Find similar trials in Gilbert, AZ

By research site
Banner - MD Anderson Cancer Center· Gilbert, AZBaptist- MD Anderson Cancer Center· Jacksonville, FLThe Queen's Medical Center· Honolulu, HISt. Luke's Cancer Institute· Boise, IDCooper Hospital UNIV MED CTR.· Camden, NJUT Southwestern/Simmons Cancer Center-Dallas· Dallas, TX

Related Studies